Ozempic (Semaglutide)

Semaglutide, the active ingredient in Ozempic, is a GLP-1 receptor agonist presented as a / injection solution for subcutaneous use. It treats type 2 diabetes mellitus in adults. GNH USA supplies Ozempic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

GNH USA supplies Ozempic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Ozempic is a GLP-1 receptor agonist used in the management of metabolic disorders:

- Type 2 diabetes mellitus: improves glycemic control and reduces HbA1c levels. - Cardiovascular risk reduction: lowers risk of major adverse cardiovascular events in adults with established cardiovascular disease. - Weight management adjunct: assists with weight loss when used alongside diet and exercise in appropriate patients.

Semaglutide may cause a range of adverse reactions, most of which are mild to moderate in intensity.

Common Side Effects: - Nausea: mild to moderate nausea is frequently reported. - Vomiting: occasional episodes may occur. - Diarrhea: loose stools are commonly observed. - Constipation: some patients experience reduced bowel movements. - Abdominal pain: discomfort in the stomach area may be reported. - Decreased appetite: reduced desire to eat is a frequent effect.

Serious or Rare Side Effects: - Pancreatitis: inflammation of the pancreas can occur. - Severe hypoglycaemia: especially when combined with insulin or sulfonylureas. - Acute kidney injury: renal function may deteriorate in susceptible individuals. - Thyroid C‑cell tumours: potential risk observed in rodent studies. - Allergic reactions: including anaphylaxis and severe skin reactions. - Gallbladder disease: increased incidence of gallstones or cholecystitis.

When prescribing Ozempic, clinicians should consider several safety aspects:

- Renal function: assess baseline kidney function and monitor periodically. - Gastrointestinal history: evaluate risk of nausea, vomiting, or pancreatitis. - Thyroid disease: avoid in patients with a personal or family history of medullary thyroid carcinoma. - Pregnancy and lactation: use only if the potential benefit justifies the risk. - Concomitant insulin or sulfonylureas: adjust doses to reduce hypoglycaemia risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Semaglutide has a limited profile of drug‑drug interactions, but clinicians should remain vigilant:

Major Interactions (Avoid): - Rapid‑acting insulin: may cause severe hypoglycaemia when combined. - Sulfonylureas: increase risk of low blood sugar.

Moderate Interactions (Monitor Closely): - Oral contraceptives: potential reduction in absorption due to delayed gastric emptying. - Warfarin: monitor INR closely as glycaemic changes may affect anticoagulation. - Digoxin: altered renal clearance may require dose adjustment. - Beta‑beta  

t